FDA Approves New U.S. Labeling for ISENTRESS® (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients

Dateline City: 

WHITEHOUSE STATION, N.J.

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
approved new labeling for ISENTRESS® (raltegravir)
Film-coated Tablets, Merck’s integrase inhibitor for the treatment of
HIV-1 infection in adult patients as part of combination HIV therapy.
Language: 

English

Contact: 

MerckMedia Contacts:Caroline Lappetito, 267-305-7639Claire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088

Ticker Slug: 

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Product News - July 1, 2013 Category: Drugs & Pharmacology Authors: hq_site_admin Tags: Prescription Medicine News Corporate News Latest News Source Type: news